Literature DB >> 9300426

Kava extract ingredients, (+)-methysticin and (+/-)-kavain inhibit voltage-operated Na(+)-channels in rat CA1 hippocampal neurons.

E I Magura1, M V Kopanitsa, J Gleitz, T Peters, O A Krishtal.   

Abstract

The action of synthetic kava pyrones, (+)-methysticin and (+/-)-kavain, on voltage-operated Na(+)-channels was studied in whole-cell patch-clamped CA1 hippocampal neurons. In doses of 1-400 microM, both compounds exerted a rapid and reversible inhibition of the peak amplitude of Na(+)-currents. Shifting holding membrane potential (Vhold) to more positive values enhanced their blocking effect. The drugs studied did not demonstrate use-dependent properties at 10 Hz stimulation but shifted H infinity curve toward more negative potentials, accelerated time-course of inactivation and slowed down the recovery from inactivation. Voltage-dependence of Na(+)-channel inhibition can be explained by interaction of (+)-methysticin and (+/-)-kavain with resting closed and inactivated states of Na(+)-channel.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9300426     DOI: 10.1016/s0306-4522(97)00177-2

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  7 in total

Review 1.  Plant-based medicines for anxiety disorders, part 2: a review of clinical studies with supporting preclinical evidence.

Authors:  Jerome Sarris; Erica McIntyre; David A Camfield
Journal:  CNS Drugs       Date:  2013-04       Impact factor: 5.749

2.  The Impact of One-week Dietary Supplementation with Kava on Biomarkers of Tobacco Use and Nitrosamine-based Carcinogenesis Risk among Active Smokers.

Authors:  Yi Wang; Sreekanth C Narayanapillai; Katelyn M Tessier; Lori G Strayer; Pramod Upadhyaya; Qi Hu; Rick Kingston; Ramzi G Salloum; Junxuan Lu; Stephen S Hecht; Dorothy K Hatsukami; Naomi Fujioka; Chengguo Xing
Journal:  Cancer Prev Res (Phila)       Date:  2020-02-26

Review 3.  Therapeutic potential of kava in the treatment of anxiety disorders.

Authors:  Yadhu N Singh; Nirbhay N Singh
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

4.  Extracts of kava (Piper methysticum) induce acute anxiolytic-like behavioral changes in mice.

Authors:  Kennon M Garrett; Garo Basmadjian; Ikhlas A Khan; Brian T Schaneberg; Thomas W Seale
Journal:  Psychopharmacology (Berl)       Date:  2003-07-04       Impact factor: 4.530

5.  Synthetic Kavalactone Analogues with Increased Potency and Selective Anthelmintic Activity against Larvae of Haemonchus contortus In Vitro.

Authors:  H M P Dilrukshi Herath; Aya C Taki; Nghi Nguyen; José Garcia-Bustos; Andreas Hofmann; Tao Wang; Guangxu Ma; Bill C H Chang; Abdul Jabbar; Brad E Sleebs; Robin B Gasser
Journal:  Molecules       Date:  2020-04-24       Impact factor: 4.411

6.  Kava for the treatment of generalised anxiety disorder (K-GAD): study protocol for a randomised controlled trial.

Authors:  Karen M Savage; Con K Stough; Gerard J Byrne; Andrew Scholey; Chad Bousman; Jenifer Murphy; Patricia Macdonald; Chao Suo; Matthew Hughes; Stuart Thomas; Rolf Teschke; Chengguo Xing; Jerome Sarris
Journal:  Trials       Date:  2015-11-02       Impact factor: 2.279

Review 7.  Kava as a Clinical Nutrient: Promises and Challenges.

Authors:  Tengfei Bian; Pedro Corral; Yuzhi Wang; Jordy Botello; Rick Kingston; Tyler Daniels; Ramzi G Salloum; Edward Johnston; Zhiguang Huo; Junxuan Lu; Andrew C Liu; Chengguo Xing
Journal:  Nutrients       Date:  2020-10-05       Impact factor: 5.717

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.